Solid Tümörlerde Kemik Metastazlarının Yönetimi
Özet
Kemik metastazları, ileri evre solid tümörlü hastaların yaklaşık üçte ikisinde görülen ve ciddi morbidite ile mortaliteye yol açan yaygın bir sağlık sorunudur. Meme, akciğer ve prostat kanserleri en sık kemik metastazı yapan primer tümörler arasında yer almaktadır. Metastazların gelişiminde tümör ve kemik mikroçevresi arasındaki karmaşık hücresel etkileşimler, özellikle OPG/RANK/RANKL ve Wnt gibi sinyal yolakları kritik roller oynamaktadır. Bu etkileşimler sonucunda osteolitik, osteoblastik veya mikst tipte kemik lezyonları ortaya çıkmaktadır. Tanı sürecinde direkt grafi, kemik sintigrafisi, bilgisayarlı tomografi (BT), manyetik rezonans görüntüleme (MRG) ve PET/BT gibi çeşitli radyolojik yöntemlerden yararlanılmaktadır. Tedavi yaklaşımı ise tamamen multimodaliter olup; ağrıyı hafifletmek, iskelet ilişkili olayları (SRE) önlemek ve hastanın yaşam kalitesini artırmak hedeflenmektedir. Bu doğrultuda denosumab ve zoledronik asit gibi osteoklast inhibitörleri, sistemik kemoterapi ve hormonal tedaviler, eksternal ışın radyoterapisi (EBRT), stereotaktik vücut radyoterapisi (SBRT), kemik hedefli radyofarmasötikler, cerrahi stabilizasyon ve lokal termal ablasyon yöntemleri hastanın genel durumuna ve beklentisine göre multidisipliner bir yaklaşımla entegre edilerek uygulanmaktadır.
Bone metastases are a common health problem seen in approximately two-thirds of patients with advanced solid tumors, leading to significant morbidity and mortality. Breast, lung, and prostate cancers are among the primary tumors that most frequently metastasize to the bone. Complex cellular interactions between the tumor and the bone microenvironment, particularly signaling pathways such as OPG/RANK/RANKL and Wnt, play critical roles in the development of metastases. These interactions result in osteolytic, osteoblastic, or mixed types of bone lesions. Various radiological methods, including direct radiography, bone scintigraphy, computed tomography (CT), magnetic resonance imaging (MRI), and PET/CT, are utilized in the diagnosis process. The treatment approach is entirely multimodal, aiming to alleviate pain, prevent skeletal-related events (SREs), and improve the patient's quality of life. Accordingly, osteoclast inhibitors like denosumab and zoledronic acid, systemic chemotherapy and hormonal therapies, external beam radiation therapy (EBRT), stereotaktik body radiation therapy (SBRT), bone-targeted radiopharmaceuticals, surgical stabilization, and local thermal ablation methods are integrated and applied through a multidisciplinary approach based on the patient's overall condition and life expectancy.
Referanslar
Hage W D, Aboulafia A J, Aboulafia D M. Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthopedic Clinics of North America 2000;31:515-528.
Coleman R E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research 2006;12: 6243-6249.
Brown J E, Webbe H N, Coleman R E. The role of bisphosphorıates in breast and prostate cancers. Endocrine-Related Cancer 2004;11: 207-224.
Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology 2000; 31: 578.
Lee YT. Breast carcinoma: pattern of metastasis at autopsy. Journal of Surgical Oncology 1983; 23:175.
Wedam SB, Beaver JA, Amiri-Kordestani L, et al. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. Journal Clinical Oncology 2018; 36: 1225.
Katakami N, Kunikane H, Takeda K, et al. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. Journal of Thoracic Oncology 2014; 9: 231.
Hernandez RK, Wade SW, Reich A, et al. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer 2018; 18:44.
Rosenthal Dİ. Radiologic diagnosis of bone metastases. Cancer 1997;15:1595-1607.
Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537.
Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes & Development 2009; 23:1882.
Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. New England Journal of Medicine 2006;354:2250–2261
Hofbauer LC, Rachner TD, Coleman RE, et al. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinology. 2014;2:500–512.
Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nature Reviews Cancer. 2011;11:411–425.
Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nature Reviews Cancer. 2016;16(6):373–386.
Woodward J K L, Holen I, Coleman R E, et al. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone. 2007;41:912–927
Rose AA, Siegel PM. Breast cancer-derived factors facilitate osteolytic bone metastasis. Bulletin du Cancer 2006;93:931–943.
Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews Clinical Oncology 2011;8:357–368.
Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. British Journal of Cancer. 2000;83:360–365.
Granchi S, Bronechi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49:267–277.
Ottewell PD, Wang N, Meek J, et al. Castrationinduced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine-Related Cancer. 2014;21:769–781.
Kirschenbaum A, Izadmehr S, Yao S, et al. Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases. Endocrinology 2016;157:4526– 4533.
Yang H L, Liu T, Wang X M, et al. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. European Radiology 2011; 21: 2604-2617.
Kim S H, Smith S E, Mulligan ME. Hematopoietic tumors and metastases involving bone. Radiologic Clinics North of America 2011; 49: 1163-1183.
O'Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World Journal of Radiology 2015; 7: 202-11.
Langsteger W, Rezaee A, Pirich C, et al. (18)FNaF-PET/CT and (99 m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Seminars of Nuclear Medicine 2016;46:491–501.
Bastawrous S, Bhargava P, Behnia F, et al. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. Radiographics 2014;34:1295–1316.
Sheikhbahaei S, Jones KM, Werner RA, et al. (18)FNaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of Nuclear Medicine 2019;33:351–361.
Terpos E, Dimopoulos M A, Moulopoulos L A. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. American Society of Clinical Oncology Education Book. 2016;35:407–417.
Jambpor I, Kuisma A, Ramadan S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET CT and whole body 1.5T MRI including DWI for the detection of bone metastases in high risk breast and prostate cancer patients: SKELTA clinical trial. Acta Oncologica. 2016;55:59–67.
Lengana T, Lawal I O, Boshomane T G, et al. (68)Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli? Clinical Genitourinary Cancer 2018; 16: 392-401.
Hofman MS, Lawrentschuk N, Francis R J,et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-1216.
Costa L, Demers L M, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predieting bone metastases status. Journal of Clinical Oncology 2002;20:850-856.
Coleman R E, VVhitaker K D, Moss D W, et al. Biochemical monitoring predicts response in bone metastases to treatment. British Journal of Cancer 1988;58:621-625.
Loberg R D, Logothetis C J, Keller E T,et al. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of Clinical Oncology 2005; 23:8232.
Barzilai O, Laufer I, Yamada Y, et al. Integrating Evidence-Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease. Journal of Clinical Oncology 2017; 35:2419.
Bollen L, Wibmer C, Van der Linden YM, et al. Predictive Value of Six Prognostic Scoring Systems for Spinal Bone Metastases: An Analysis Based on 1379 Patients. Spine (Phila Pa 1976) 2016; 41:155.
Paulino Pereira N R, Mclaughlin L, Janssen S J, et al. The SORG nomogram accurately predicts 3- and 12-months survival for operable spine metastatic disease: External validation. Journal of Surgical Oncology 2017; 115:1019.
Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthopaedica Scandinavica 1995; 66:143.
Ghori AK, Leonard DA, Schoenfeld AJ, et al. Modeling 1-year survival after surgery on the metastatic spine. Spine Journal 2015; 15:2345.
Alcorn SR, Fiksel J, Wright JL, et al. Developing an Improved Statistical Approach for Survival Estimation in Bone Metastases Management: The Bone Metastases Ensemble Trees for Survival (BMETS) Model. International Journal of Radiation Oncology - Biology - Physics (IJROBP) 2020; 108:554.
Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353:1695.
Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control 2012; 19:154.
Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer 2012; 48:3082.
O'Carrigan B, Wong M H, Willson M L, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database System Review 2017; 10:3474.
Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research 2012; 18:4841.
Vadhan-Raj S, von Moos R, Fallowfield L J, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Annals of Oncology 2012; 23:3045.
Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 2009; 7 Suppl 3:S1.Fleisch H. Bisphosphonates: mechanisms of action. Endocrine Reviews 1998; 19:80.
Van Poznak C, Somerfield MR, Barlow WE, et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology 2017; 35:3978.
MSTS, ASTRO, ASCO: The treatment of metastatic carcinoma and myeloma of the femur: Clinical practice guideline. Available at: http://msts.org/view/download.php/education/mbd-cpg-amended (Accessed on December 02, 2020)
Stopeck A T, Lipton A, Body J J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology 2010; 28:5132.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology 2011; 29:1125.
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813.
Bekker P J, Holloway D L, Rasmussen A S, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone Mineral Research 2004; 19:1059.
Gough N, Miah A B, Linch M. Nonsurgical oncological management of cancer pain. Current Opinion Support Palliative Care 2014; 8:102.
Tannock I F, de Wit R, Berry W R, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 2004; 351:1502.
Hartsell W F, Scott C B, Bruner D W, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. Journal of the National Cancer Institute 2005; 97:798
Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. International Journal of Radiation Oncology - Biology - Physics (IJROBP) 2011; 79:965.
Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology 2020; 31:1650.
Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology 2017; 7:4.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393:2051.
Nguyen Q N, Chun S G, Chow E, et al. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncology 2019; 5:872.
Wood T J, Racano A, Yeung H, et al. Surgical management of bone metastases: quality of evidence and systematic review. Annals of Surgical Oncology 2014; 21:4081.
Ratasvuori M, Wedin R, Hansen B H, et al. Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. Journal of Surgical Oncology 2014; 110:360.
Chen CY, Huang KG, Abdullah NA, et al. Successful treatment of isolated fibular bone metastasis in a uterine endometrial cancer of clear cell carcinoma. European Journal of Gynaecologic Oncology 2013; 34:347.
Lequaglie C, Massone PB, Giudice G, et al. Gold standard for sternectomies and plastic reconstructions after resections for primary or secondary sternal neoplasms. Annals of Surgical Oncology 2002; 9:472.
Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. Journal of Bone Joint Surgery 2007; 89:1794.
Onesti JK, Mascarenhas CR, Chung MH, Davis AT. Isolated metastasis of colon cancer to the scapula: is surgical resection warranted? World Journal Surgical Oncology 2011; 9:137.
Yasko AW, Rutledge J, Lewis VO, Lin PP. Disease- and recurrence-free survival after surgical resection of solitary bone metastases of the pelvis. Clinical Orthopaedics and Related Research 2007; 459:128.
Fisher C G, DiPaola C P, Ryken T C, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976) 2010; 35:1221.
Fourney D R, Frangou E M, Ryken T C, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. Journal of Clinical Oncology 2011; 29:3072.
